Clinuvel Pharmaceuticals vs Cytokinetics
Cytokinetics is the larger business, with $88.0m of revenue in fiscal 2025 against $64.3m for Clinuvel Pharmaceuticals (1.4 times as much). Cytokinetics grew faster (376.6% against 5.2%). Clinuvel Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 36.0% against -891.6%.
| Latest fiscal year | Clinuvel PharmaceuticalsCUVL, 2026 | CytokineticsCYTK, 2025 |
|---|---|---|
| Revenue | $64.3m | $88.0m |
| Revenue growth | 5.2% | 376.6% |
| Net income | $23.2m | −$785m |
| Operating margin | 43.4% | -695.4% |
| Net margin | 36.0% | -891.6% |
| Return on equity | 13.4% | — |
| Free cash flow | $11.8m | −$535m |
| Cash | $13.9m | $123m |
| Total debt | $0 | $999m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 673 |
| Market value | $256m | $7.69bn |
| Price vs our value range | — | — |
| Moat score | — | 9 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 85 sales |